Leaning on tech expertise, Peninsula gene-editing company raises $110 million, targets lower-priced drugs
October 23, 2018 at 09:56 AM EDT
From Redwood City — between tech and biotech hotspots — the five-year-old company is tapping the best of both industries to standardize CRISPR gene-editing technology that ultimately could lower the cost of research into cell and gene therapies.
